These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38804098)

  • 61. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.
    Landgren O; Zeig-Owens R; Giricz O; Goldfarb D; Murata K; Thoren K; Ramanathan L; Hultcrantz M; Dogan A; Nwankwo G; Steidl U; Pradhan K; Hall CB; Cohen HW; Jaber N; Schwartz T; Crowley L; Crane M; Irby S; Webber MP; Verma A; Prezant DJ
    JAMA Oncol; 2018 Jun; 4(6):821-827. PubMed ID: 29710195
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.
    Altrock PM; Ferlic J; Galla T; Tomasson MH; Michor F
    JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652561
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dietary intake is associated with risk of multiple myeloma and its precursor disease.
    Thordardottir M; Lindqvist EK; Lund SH; Costello R; Burton D; Steingrimsdottir L; Korde N; Mailankody S; Eiriksdottir G; Launer LJ; Gudnason V; Harris TB; Landgren O; Torfadottir JE; Kristinsson SY
    PLoS One; 2018; 13(11):e0206047. PubMed ID: 30383820
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
    Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets.
    Steiner N; Müller U; Hajek R; Sevcikova S; Borjan B; Jöhrer K; Göbel G; Pircher A; Gunsilius E
    PLoS One; 2018; 13(8):e0202045. PubMed ID: 30096165
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.
    Lehners N; Ellert E; Xu J; Hillengass J; Leichsenring J; Stenzinger A; Goldschmidt H; Andrulis M; Raab MS
    Leuk Lymphoma; 2018 Nov; 59(11):2660-2669. PubMed ID: 29616856
    [TBL] [Abstract][Full Text] [Related]  

  • 68. MALDI-TOF analysis of blood serum proteome can predict the presence of monoclonal gammopathy of undetermined significance.
    Barceló F; Gomila R; de Paul I; Gili X; Segura J; Pérez-Montaña A; Jimenez-Marco T; Sampol A; Portugal J
    PLoS One; 2018; 13(8):e0201793. PubMed ID: 30071092
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Tienhaara A; Pelliniemi TT
    Clin Lab Haematol; 1994 Sep; 16(3):213-23. PubMed ID: 7828409
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance.
    İşgör İŞ; Toptaş T; Türkoz HK
    Turk J Haematol; 2022 Dec; 39(4):245-253. PubMed ID: 35965418
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Carulli G; Ottaviano V; Cannizzo E; Giuntini S; Manetti C; Ciancia EM; Azzarà A
    Clin Ter; 2012; 163(5):387-92. PubMed ID: 23099966
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.
    Landgren O; Shim YK; Michalek J; Costello R; Burton D; Ketchum N; Calvo KR; Caporaso N; Raveche E; Middleton D; Marti G; Vogt RF
    JAMA Oncol; 2015 Nov; 1(8):1061-8. PubMed ID: 26335650
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Proteomic profiling in plasma cell disorders: a feasibility study.
    Mailankody S; Devlin SM; Korde N; Lendvai N; Lesokhin A; Landau H; Hassoun H; Ballagi A; Ekman D; Chung DJ; Patel M; Koehne G; Giralt S; Landgren O
    Leuk Lymphoma; 2017 Jul; 58(7):1757-1759. PubMed ID: 27908223
    [No Abstract]   [Full Text] [Related]  

  • 78. Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.
    Crowley MP; Quinn S; Coleman E; Eustace JA; Gilligan OM; O'Shea SI
    J Thromb Thrombolysis; 2015 Feb; 39(2):245-9. PubMed ID: 25271000
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
    Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
    BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma.
    Laurenzana I; Trino S; Lamorte D; Girasole M; Dinarelli S; De Stradis A; Grieco V; Maietti M; Traficante A; Statuto T; Villani O; Musto P; Sgambato A; De Luca L; Caivano A
    Int J Nanomedicine; 2021; 16():3141-3160. PubMed ID: 33994784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.